<DOC>
	<DOCNO>NCT00502515</DOCNO>
	<brief_summary>The primary objective sudy assess effect two dos SSR180575 rate regeneration epidermal nerve fiber follow denervation epidermal layer capsaicin patient diabetes mellitus mild peripheral neuropathy . Secondary objective explore efficacy SSR180575 clinical assessment , nerve function measure assess tolerability safety SSR180575 . The treatment period 6 month .</brief_summary>
	<brief_title>Dose-effect SSR180575 Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Patients diagnose Diabetes Mellitus , type I II , treat untreated Diabetic neuropathy treat untreated Patients unstable glycemic control Patients hospitalize diabetes complication 3 month prior randomization Patients peripheral neuropathy attributable cause diabetes Nonmeasurable sural nerve sensory response nerve conduction study Amputation part low extremity Patients history myocardial infarction know coronary artery disease Grade III IV heart failure New York Heart Association criteria The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Neuropathy</keyword>
</DOC>